סמן גנטי חדש לזהוי סרטן ערמונית אלים

New Genetic Marker For Prostate Cancer Aggressiveness 18 Jul 2007 Scientists at The Institute of Cancer Research AND at the Wolfson Institute of Preventive Medicine, funded by Cancer Research UK AND the National Cancer Research Institute, have discovered a genetic change that identifies a particularly aggressive form of prostate cancer. Prostate cancer is different from many other cancers in that only certain types require treatment. This development could play a crucial role in the decision of whether OR not to treat prostate cancer patients. Prostate cancer is now the most common male cancer in the UK; each year, nearly 32,000 men are diagnosed AND 10,000 men lose their lives to the disease. In new research published last week in Oncogene, researchers have shown that prostate cancer patients with a particular genetic change have extremely poor survival rates. Prostate cancers commonly contain fusion of the TMPRSS2 AND ERG genes. The new study shows that duplication of this change, called 2+Edel, is found in 6.6% of prostate cancers (equivalent to 1,800 UK prostate cancers patients each year). Patients with 2+Edel have only a 25% survival rate after eight years, compared to 90% for patient with no alterations in this region of DNA. The work represents a collaboration between Professor Colin Cooper at The Institute of Cancer Research AND Professor Jack Cuzick at the Wolfson Institute of Preventive Medicine. Prostate cancer is unique as in the majority of cases it will be slow growing AND may only start to cause symptoms after many years. However, in some men the cancer will grow AND spread, becoming fatal. At present it is very difficult to distinguish between prostate cancers which require treatment (called Tigers) AND those which do not (called Pussycats) so men diagnosed with prostate cancer are presented with a unique problem of whether to undergo treatment, which is often associated with debilitating side effects such as impotence AND incontinence. Professor Colin Cooper, The Grand Charity of Freemasons' Chair of Molecular Biology at The Institute of Cancer Research said: "This is exciting news for men with prostate cancer, many of whom are faced with the difficult decision of whether to undergo treatment OR not. We are currently conducting ongoing studies looking at 2+Edel in prostate cancer patients. We hope that in the next few years screening for 2+Edel will be incorporated into clinical practice AND used alongside current techniques, such as Gleason scoring, at the time of diagnosis to decide whether men require treatment OR not." Currently a system called the Gleason score is used to grade which cancers require treatment AND which do not. Whilst the Gleason score is extremely useful, it is subject to variability in interpretation. Therefore, new techniques to support the Gleason score are urgently required. The researchers retrospectively analysed the ERG gene in samples from 455 men with prostate cancer who had been conservatively managed. The article, by Professor Cooper, Professor Cuzick AND colleagues entitled 'Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer' will be published in online in Oncogene: doi: 10.1038/sj.onc.1210640,16 July 2007 at 5pm

לפני שלוש שנים החלה עלייה של PSA מ- 2.5 בהדרגה עלה ל-6 לפני 6 חודשים היתה קפיצה ל12 ואחרי חודשיים ירידה ל6 ועכשיו חודשיים 5 אני משתין בצורה תכופה אך ללא בעיות נוספות מה דעתכם אם אפשר אשמח לתשובה באימייל המצ"ב